{"generic":"Mesna","drugs":["Mesna","Mesnex"],"mono":{"0":{"id":"922326-s-0","title":"Generic Names","mono":"Mesna"},"1":{"id":"922326-s-1","title":"Dosing and Indications","sub":{"0":{"id":"922326-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hemorrhagic cystitis, Cyclophosphamide-induced; Prophylaxis:<\/b> optimal dose and timing not defined<\/li><li><b>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis:<\/b> IV regimen, mesna IV bolus 20% of ifosfamide dose (weight by weight) at the time of the ifosfamide infusion, and at 4 and 8 hours afterward; repeat each day that ifosfamide is given; maintain the ratio of mesna to ifosfamide when ifosfamide dosage is changed<\/li><li><b>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis:<\/b> IV\/oral regimen, mesna IV bolus 20% of ifosfamide dose (weight by weight) at time of infusion, oral tablets 40% of ifosfamide dose at 2 and 6 hours afterward; repeat each day that ifosfamide is given; maintain the ratio of mesna to ifosfamide when ifosfamide dosage is changed; safety and efficacy of mesa IV\/oral regimen not established with ifosfamide doses greater than 2 g\/m(2)\/day; if vomiting occurs within 2 hours of oral tablet, repeat dose or give IV mesna<\/li><li><b>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis:<\/b> continuous IV regimen (non-FDA-approved regimen), bolus dose (20% total ifosfamide dose), then 40% of ifosfamide dose as continuous IV infusion continuing for 12 to 24 hours after the completion of the ifosfamide infusion (guideline dosing)<\/li><li><b>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis:<\/b> MAID regimen for soft tissue sarcoma: doxorubicin 60 mg\/m(2) and dacarbazine 1000 mg\/m(2), mixed or administered separately via continuous IV infusion over 4 days, ifosfamide 6000 mg\/m(2) and mesna 10,000 mg\/m(2) mixed or infused separately over 3 days (ifosfamide) and 4 days (mesna); repeat every 21 days if tolerated; used in a clinical trial<\/li><li><b>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis:<\/b> MAID regimen for soft tissue sarcoma: doxorubicin 60 mg\/m(2) and dacarbazine 900 mg\/m(2), mixed and administered through central venous access via continuous IV infusion over 3 days, ifosfamide 7500 mg\/m(2) and mesna 10,000 mg\/m(2) mixed or infused separately through a peripheral line via a continuous IV infusion over 3 days (ifosfamide) and 4 days (mesna); repeat every 21 days if tolerated; used in a clinical trial<\/li><\/ul>"},"1":{"id":"922326-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"922326-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Hemorrhagic cystitis, Cyclophosphamide-induced; Prophylaxis<br\/>"}}},"3":{"id":"922326-s-3","title":"Contraindications\/Warnings","sub":[{"id":"922326-s-3-9","title":"Contraindications","mono":"hypersensitivity to mesna or any component of the product <br\/>"},{"id":"922326-s-3-10","title":"Precautions","mono":"<ul><li>benzyl alcohol toxicity may occur; increased risk in patients receiving high-dose therapy; monitoring recommended<\/li><li>dermatologic toxicity, including symptoms consistent with drug reaction with eosinophilia and systemic (DRESS), Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN), have occurred with first exposure to several months after treatment initiation; discontinue and institute appropriate care if occurs<\/li><li>hypersensitivity reactions, systemic (eg, anaphylaxis, fever, cardiovascular symptoms, acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema), may occur with first exposure to several months after treatment initiation; monitoring recommended; discontinue and institute appropriate care if occurs<\/li><li>hypersensitivity to other thiol compounds, history; may increase risk for mesna hypersensitivity<\/li><li>infants and neonates, premature or low-birthweight (unapproved use); avoid use; injection solution contains benzyl alcohol<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"922326-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"922326-s-3-12","title":"Breast Feeding","mono":"Micromedex: Milk effects are possible.<br\/>"}]},"4":{"id":"922326-s-4","title":"Drug Interactions","sub":{"2":{"id":"922326-s-4-15","title":"Moderate","mono":"<ul>Warfarin (probable)<\/ul>"}}},"5":{"id":"922326-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (8.4% to 9.2%), Edema (6.7% to 7.6%), Edema of face (4.2% to 5%), Peripheral edema (6.7%)<\/li><li><b>Dermatologic:<\/b>Alopecia (10.1% to 10.9%), Diaphoresis (1.7% to 7.6%)<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia (8.4% to 9.2%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (11.8% to 15.1%), Constipation (17.6% to 23.5%), Diarrhea (7.6% to 14.3%), Loss of appetite (16% to 17.6%), Nausea (53.8% to 54.6%), Vomiting (29.4% to 37.8%)<\/li><li><b>Hematologic:<\/b>Anemia (16.8% to 17.6%), Granulocytopenic disorder (12.6% to 13.4%), Leukopenia (17.6% to 21%), Thrombocytopenia (13.4% to 17.6%)<\/li><li><b>Musculoskeletal:<\/b>Backache (5% to 6.7%)<\/li><li><b>Neurologic:<\/b>Asthenia (12.6% to 17.6%), Confusion (5% to 5.9%), Dizziness (4.2% to 7.6%), Headache (7.6% to 10.9%), Insomnia (5% to 9.2%), Somnolence (6.7% to 10.1%)<\/li><li><b>Psychiatric:<\/b>Anxiety (3.4% to 5.9%)<\/li><li><b>Respiratory:<\/b>Dyspnea (9.2%)<\/li><li><b>Other:<\/b>Fatigue (20.2%), Fever (15.1% to 20.2%), Pain (7.6% to 8.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Drug-induced rash<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"922326-s-6","title":"Drug Name Info","sub":{"0":{"id":"922326-s-6-17","title":"US Trade Names","mono":"Mesnex<br\/>"},"2":{"id":"922326-s-6-19","title":"Class","mono":"Hemorrhagic Cystitis Inhibitor<br\/>"},"3":{"id":"922326-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"922326-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"922326-s-7","title":"Mechanism Of Action","mono":"Mesna reduces ifosfamide-induced hemorrhagic cystitis by binding to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. and by binding to the double bonds of acrolein and other urotoxic ifosfamide metabolites thereby inhibiting their toxic effects on the bladder.<br\/>"},"8":{"id":"922326-s-8","title":"Pharmacokinetics","sub":[{"id":"922326-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, oral: 58% (free mesna); 89% (total mesna)<\/li><li>Effects of food: None<\/li><li>Tmax, oral: 1.5 to 4 hours (free mesna); 3 to 7 hours (total mesna)<\/li><\/ul>"},{"id":"922326-s-8-24","title":"Distribution","mono":"Vd: 0.652 L\/kg <br\/>"},{"id":"922326-s-8-25","title":"Metabolism","mono":"Metabolite: Dimesna (mesna disulfide) <br\/>"},{"id":"922326-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 32% (mesna); 33% (dimesna metabolite).<\/li><li>Plasma: 1.23 L\/hr\/kg<\/li><\/ul>"},{"id":"922326-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Mesna: 0.36 hours<\/li><li>Dimesna: 1.17 hours<\/li><\/ul>"}]},"9":{"id":"922326-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>dilute with D5W, NS, LR, D5-0.2%NaCl, D5-0.33%NaCl, or D5-0.45%NaCl to a final concentration of 20 mg\/mL<\/li><li>following initial puncture of multidose vial, use within 8 days<\/li><li>following dilution, store at 25 degrees C (77 degrees F) and use within 24 hours<\/li><li>if mixed with ifosfamide in the same IV bag, do not exceed a final ifosfamide concentration of 50 mg\/mL<\/li><li>do not mix with epirubicin, cyclophosphamide, cisplatin, carboplatin, or nitrogen mustard<\/li><li>administer as an IV bolus injection<\/li><\/ul>"},"10":{"id":"922326-s-10","title":"Monitoring","mono":"<ul><li>decrease in ifosfamide-induced hemorrhagic cystitis may indicate efficacy<\/li><li>urine: presence of hematuria<\/li><li>systemic hypersensitivity reaction, signs and symptoms may occur with first exposure or after several months of exposure<\/li><li>(injection) benzyl alcohol toxicity, signs and symptoms, especially in patients receiving high dosages<\/li><\/ul>"},"11":{"id":"922326-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Solution: 100 MG\/ML<br\/><\/li><li><b>Mesnex<\/b><br\/><ul><li>Intravenous Solution: 100 MG\/ML<\/li><li>Oral Tablet: 400 MG<\/li><\/ul><\/li><li><b>NovaPlus Mesna<\/b><br\/>Intravenous Solution: 100 MG\/ML<br\/><\/li><li><b>PremierPro RX Mesna<\/b><br\/>Intravenous Solution: 100 MG\/ML<br\/><\/li><\/ul>"},"12":{"id":"922326-s-12","title":"Toxicology","sub":[{"id":"922326-s-12-31","title":"Clinical Effects","mono":"<b>MESNA <\/b><br\/>OVERDOSE: No human data available. ADVERSE EFFECTS: Nausea vomiting, and diarrhea are common at high doses. Hypokalemia and rashes have been reported. The drug has an unpleasant smell and causes increased inspiratory but not expiratory resistance when inhaled. <br\/>"},{"id":"922326-s-12-32","title":"Treatment","mono":"<b>MESNA <\/b><br\/><ul><li>Support: Care is symptomatic and supportive. Treat nausea and vomiting with antiemetics. Administer intravenous fluids and replete potassium as needed.<\/li><li>Decontamination: Activated charcoal.<\/li><li>Monitoring of patient: Monitor serum electrolytes.<\/li><\/ul>"},{"id":"922326-s-12-33","title":"Range of Toxicity","mono":"<b>MESNA<\/b><br\/>TOXIC: Dose not established. GI side effects more common at doses of 80 mg\/kg. THERAPEUTIC: Adult: Intravenously administered simultaneously with ifosfamide at a dose of 20% of the ifosfamide dose, then repeated 4 and 8 hours after the ifosfamide. Oral mesna may be substituted for the second and third dose; oral mesna at 40% of the ifosfamide dose is administered at 2 and 6 hours after the ifosfamide. Intravenous infusions of 2500 mg\/m(2)\/day are used in other regimens. Pediatric: A dose of 25% of the ifosfamide dose given as 15 minutes, 4 hours and 6 hours after ifosfamide infusion has been used in a small number of children and adolescents. <br\/>"}]},"13":{"id":"922326-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include nausea, vomiting, constipation, anorexia, fatigue, or fever.<\/li><li>Instruct patient to report signs or symptoms of hematuria or dermatologic reactions.<\/li><li>Encourage patient to drink 1 to 2 liters of fluid each day during therapy.<\/li><li>Instruct patients who vomit within 2 hours of taking oral mesna to notify healthcare professional. The dose may need to be repeated.<\/li><li>Advise patient to contact healthcare professional for instructions if a dose is missed.<\/li><\/ul>"}}}